Cancer Immunology, Immunotherapy

, Volume 32, Issue 2, pp 117–124 | Cite as

Enhanced tumor susceptibility of immunocompetent mice infected with lymphocytic choriomeningitis virus

  • Markus Kohler
  • Barbara Rüttner
  • Suzanne Cooper
  • Hans Hengartner
  • Rolf M. Zinkernagel
Original articles


Mice infected i.v. with high doses of lymphocytic choriomeningitis virus (LCMV; 105–106 plaqueforming units) 8–10 days prior to challenge with the methylcholanthrene-induced fibrosarcoma tumor cell line MC57G or the melanoma cell line B16 tumor cells showed an enhanced tumor susceptibility with respect to both growth kinetics of the tumor and the minimal dose necessary for tumor take. After transient initial growth, MC57G tumor cells were all rejected by uninfected C57BL/6 mice by day 14. Mice preinfected i.v. with LCMV 3 weeks before or at the time of tumor challenge, but not those infected 2 months before or 7 days after, showed increasing tumor growth, the tumor take being 100% for 106, 50% for 105 and 37% for 104 MC57G tumor cells injected into the footpad compared with resistance to 106 cells in normal mice. B16 melanoma cells also grew more rapidly in LCMV-preinfected mice and by day 40 tumors were established with about 100 times fewer cells, i.e. about 103 compared with 3×104−3×105 for uninfected mice. Analysis of the growth of tumor cells in normal and in LCMV-carrier mice revealed that the latter mice were not more susceptible to LCMV-infected than to uninfected MC57G. Since LCMV-carrier mice fail to mount LCMV-specific T cell responses, these results suggest that anti-LCMV-specific T cells may be responsible for acquired immunodeficiency hampering immune surveillance against the tumors studied.


Melanoma Melanoma Cell Tumor Cell Line Melanoma Cell Line Fibrosarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aden DP, Knowles BB (1976) Cell surface antigen coded for the human chromosome 7. Immunogenetics 3: 209Google Scholar
  2. 2.
    Ahmed R, King C, Oldstone MBA (1987) Virus-lymphocyte interaction: T cells of the helper subset are infected with lymphocytic choriomeningitis virus during persistent infection in vivo. J Virol 61: 1571Google Scholar
  3. 3.
    Bekesi JG, St-Arneault G, Holland JF (1972) Immunogenicity of leukemia L1210 cells after neuraminidase treatment. J Natl Cancer Inst 49: 107Google Scholar
  4. 4.
    Boog CJP, Boes J, Melief CJM (1988) Stimulation with dendritic cells decreases or obviates the CD4+ helper cell requirement in cytotoxic T lymphocyte responses. Eur J Immunol 18: 219Google Scholar
  5. 5.
    Boone CW, Blackman K (1972) Augmented immunogenicity of tumor cell homogenates infected with influenza virus. Cancer Res 32: 1018Google Scholar
  6. 6.
    Bro-Jörgensen K, Volkert M (1974) Defect in the immune system of mice infected with lymphocytic choriomeningitis virus. Infect Immun 9: 605Google Scholar
  7. 7.
    Buchmeier MJ, Welsh RM, Dutko FJ, Oldstone MBA (1980) The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol 30: 275Google Scholar
  8. 8.
    Centers of Disease Control Task Force (1982) Epidemiological aspects of the current outbreak of Kaposi's sarcoma and opportunistic infections. N Engl J Med 306: 248Google Scholar
  9. 9.
    Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H (1984) Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature 312: 548Google Scholar
  10. 10.
    Cole GA, Nathanson N, Prendergast RA (1972) Requirement for thetabearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease. Nature 238: 335Google Scholar
  11. 11.
    Doherty PC, Zinkernagel RM (1974) T cell-mediated immunopathology in viral infection. Transplant Rev 19: 89Google Scholar
  12. 12.
    Fauci AS (1988) The human immunodeficiency virus: Infectivity and mechanisms of pathogenesis. Science 239: 617Google Scholar
  13. 13.
    Fernandez-Cruz E, Woda BA, Feldman JD (1980) Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes J Exp Med 152: 823Google Scholar
  14. 14.
    Fidler IJ (1973) Selection of successive tumor lines for metastasis. Nature 242: 148Google Scholar
  15. 15.
    Fidler IJ, Nicolson GL (1976) Brief communication: organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst 57: 1199Google Scholar
  16. 16.
    Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T (1984) Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression. J Immunol 132: 1571Google Scholar
  17. 17.
    Fujiwara H, Yoshioka T, Shima J, Kosugi A, Itoh K, Hamaoka T (1986) Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses. J Immunol 136: 2715Google Scholar
  18. 18.
    Gold K, Thomas D, Garret TJ (1982) Aggressive Kaposi's sarcoma in a heterosexual drug addict (New York City). N Engl J Med 307: 498Google Scholar
  19. 19.
    Hamburg V, Svet-Moldavsky G (1967) Suppression of viral and chemical carcinogenesis by means of artificial heterogenization. Nature 215: 230Google Scholar
  20. 20.
    Hotchin J (1971) Persistent and slow virus infections. Monogr Virol 3: 1Google Scholar
  21. 21.
    Jacobson S, Friedman RM, Pfau CJ (1981) Interferon induction by lymphocytic choriomeningitis viruses correlates with maximum virulence. J Gen Virol 57: 275Google Scholar
  22. 22.
    Lehmann-Grube F (1971) Lymphocytic choriomeningitis virus. Virol Monogr 10: 1Google Scholar
  23. 23.
    Lehmann-Grube F (1984) Bacterial and viral inhibition and modulation of host defences. Academic Press, London, pp 211–242Google Scholar
  24. 24.
    Lehmann-Grube F, Ambrassat J (1977) A new method to detect lymphocytic choriomeningitis virus-specific antibody in human sera. J Gen Virol 37: 85Google Scholar
  25. 25.
    Lehmann-Grube F, Assmann-Wischer U, Löliger C, Moskophidis D, Löhler J (1985) Mechanism of recovery from acute virus infection. I. Role of T lymphocytes in clearance of lymphocytic choriomeningitis virus from spleens of mice. J Immunol 134: 608Google Scholar
  26. 26.
    Leist TP, Cobbold SP, Waldmann H, Aguet M, Zinkernagel RM (1987) Functional analysis of T lymphocyte subsets in antiviral host defense, J Immunol 138: 2278Google Scholar
  27. 27.
    Leist TP, Eppler M, Rüedi E, Zinkernagel RM (1988) Virus triggered AIDS in mice is a T cell mediated immunopathology caused by virus-specific cytotoxic T cells: prevention by tolerance or by treatment with anti-CD8 antibodies. J Exp Med 167: 1749Google Scholar
  28. 28.
    Leist TP, Eppler M, Zinkemagel RM (1989) Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-IFN gamma-treated mice. J Virol 63: 2813Google Scholar
  29. 29.
    Levy JA, Ziegler JL (1983) Acquired immune deficiency syndrome (AIDS) is an opportunistic infection and Kaposi's sarcoma results from secondary immune stimulation. Lancet 2: 78Google Scholar
  30. 30.
    Lindenmann J, Klein PA (1967) Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med 126: 93Google Scholar
  31. 31.
    Löhler J, Lehmann-Grube F (1981) Immunopathologic alterations of lymphatic tissues of mice infected with lymphocytic choriomeningitis virus. I Histopathologic findings. Lab Invest 44: 193Google Scholar
  32. 32.
    Mims CA (1966) Immunofluorescene study of the carrier state and mechanism of vertical transmission in lymphocytic choriomeningitis virus infection in mice. Pathol Bacteriol 91: 395Google Scholar
  33. 33.
    Mims CA, Subrahmanyan TP (1966) Immunofluorescence study of the mechanism of resistance to superinfection in mice carrying the lymphocytic choriomeningitis virus. J Pathol Bacteriol 91: 403Google Scholar
  34. 34.
    Mims CA, Wainwright S (1968) The immunodepressive action of lymphocytic choriomeningitis virus in mice. J Immunol 101: 717Google Scholar
  35. 35.
    Minato N, Bloom BR, Jones Ch, Holland J, Reid LM (1979) Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice. J Exp Med 119: 1117Google Scholar
  36. 36.
    Molomut N, Padnos M, Gross L, Satory V (1964) Inhibition of a transplantable murine leukaemia by a lymphocytopenic virus. Nature 204: 1003Google Scholar
  37. 37.
    Moore A (1960) The oncolytic viruses. Prog Exp Tumor Res 1: 411Google Scholar
  38. 38.
    Oldstone MBA, Tishon A, Chiller JM, Weigle WO, Dixon FJ (1973) Effect of chronic viral infection on the immune system: I. comparison of the immune responsiveness of mice chronically infected with LCM virus with that of noninfected mice. J Immunol 110: 1268Google Scholar
  39. 39.
    Popescu M, Löhler J, Lehmann-Grube F (1979) Infectious lymphocytes in lymphocytic choriomeningitis virus carrier mice. J Gen Virol 42: 481Google Scholar
  40. 40.
    Quinn TC, Mann JM, Curran JW, Piot P (1986) AIDS in africa: an epidemiologic paradigm. Science 234: 955Google Scholar
  41. 41.
    Rogers MF, Morens DM, Stewart JA et al. (1983) National casecontrol study of Kaposi's sarcoma and pneumocystis carinii pneumonia in homosexual men: II. Laboratory results. Ann Intern Med 99: 151Google Scholar
  42. 42.
    Roost HP, Charan S, Gobet R, Rüedi E, Hengartner H, Althage A, Zinkernagel RM (1988) An acquired immunodeficiency in mice caused by infection with lymphocytic choriomeningitis virus. Eur J Immunol 18: 511Google Scholar
  43. 43.
    Schroff R, Gottlieb MS, Prince HE et al. (1983) Immunological studies of homosexual men with immunodeficiency and Kaposi's sarcoma. Clin Immunol Immunopathol 27: 300Google Scholar
  44. 44.
    Shearer GM (1986) AIDS: an autoimmune pathologic model for the destruction of a subset of helper T lymphocytes. Mount Sinai 53: 609Google Scholar
  45. 45.
    Takai Y, Kosugi A, Yoshioka T, Tomita S, Fujiwara H, Hamaoka T (1985) T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) respones: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses. J Immunol 134: 108Google Scholar
  46. 46.
    Traub E (1936) Persistence of lymphocytic choriomeningitis virus in immune animals and its relation to immunity. J Exp Med 63: 847Google Scholar
  47. 47.
    Traub E (1962) Can LCMV virus cause lymphomatosis in mice? Arch Gesamte Virusforsch 11: 667Google Scholar
  48. 48.
    Van Pel A, Boon Th (1982) Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 79: 4718Google Scholar
  49. 49.
    Walker CM, Moody DJ, Stites DP, Levy JA (1986) CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234: 1563Google Scholar
  50. 50.
    Welsh RM, Zinkernagel RM (1977) Heterospecific cytotoxic cells during acute lymphocytic choriomeningitis virus infection. Nature 268: 646Google Scholar
  51. 51.
    Wheelock EF, Toy ST (1973) Participation of lymphocytes in viral infections. Adv Immunol 16: 123Google Scholar
  52. 52.
    Wise KS (1977) Vesicular stomatitis virus-infected L1210 murine leukemia cells: increased immunogenicity and altered surface antigens. J Natl Cancer Inst 58: 83Google Scholar
  53. 53.
    Youn JK, Barski G (1966) Interference between lymphocytic choriomeningitis and rauscher leukemia in mice. J Natl Cancer Inst 37: 381Google Scholar
  54. 54.
    Yu AS, Bernstein ID (1982) T helper cells in immune mice amplify the primary anti-tumor cytotoxic response. J Immunol 129: 856Google Scholar
  55. 55.
    Zeigler JL, Stites DP (1986) Hypothesis: AIDS is an autoimmune disease directed at the immune system and triggered by a lymphotropic retrovirus. Clin Immunol Immunopathol 41: 305Google Scholar
  56. 56.
    Zinkernagel RM (1988) Virus triggered AIDS is a T cell mediated immunopathology: prevention by tolerance or by treatment with anti-CD8 antibodies. Immunol Today 9: 370Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Markus Kohler
    • 1
  • Barbara Rüttner
    • 1
  • Suzanne Cooper
    • 1
  • Hans Hengartner
    • 1
  • Rolf M. Zinkernagel
    • 1
  1. 1.Laboratory of Experimental Pathology, Institute of PathologyUniversity of ZurichSwitzerland

Personalised recommendations